Polypharmacy in multiple sclerosis: More is not necessarily better

Abstract

Get full access to this article

View all access options for this article.

References

Frahm

Hecker

Zettl

UK.

Polypharmacy among patients with multiple sclerosis: A qualitative systematic review. Expert Opin Drug Saf 2020; 19(2): 139–145.

Thelen

Zvonarev

Lam

, et al Polypharmacy in multiple sclerosis: Current knowledge and future directions. Mo Med 2021; 118(3): 239–245.

Cameron

Karstens

Hoang

, et al Medications are associated with falls in people with multiple sclerosis: A prospective cohort study. Int J MS Care 2015; 17(5): 207–214.

Oken

Flegal

Zajdel

, et al Cognition and fatigue in multiple sclerosis: Potential effects of medications with central nervous system activity. J Rehabil Res Dev 2006; 43(1): 83–90.

Chertcoff

Zhu

, et al Polypharmacy and multiple sclerosis: A population-based study. Mult Scler J 2020.

Halli-Tierney

Scarbrough

Carroll

Polypharmacy: Evaluating risks and deprescribing. Am Fam Physician 2019; 100: 32–38.

Fried

O’Leary

Towle

, et al Health outcomes associated with polypharmacy in community-dwelling older adults: A systematic review. J Am Geriatr Soc 2014; 62(12): 2261–2272.

Kuehn

BM.

Growing role of gabapentin in opioid-related overdoses highlights misuse potential and off-label prescribing practices. JAMA. Epub ahead of print 07 September 2022. DOI: 10.1001/jama.2022.13659.

Romskaug

Skovlun

Straand

, et al Effect of clinical geriatric assessments and collaborative medication reviews by geriatrician and family physician for improving health-related quality of life in home-dwelling older patients receiving polypharmacy: A cluster randomized clinical trial. JAMA Intern Med 2020; 180: 181–189.

10.

Scott

Hilmer

Reeve

, et al Reducing inappropriate polypharmacy: The process of deprescribing. JAMA Intern Med 2015; 175(5): 827–834.

11.

Reeve

Thompson

Farrell

Deprescribing: A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med 2017; 38: 3–11.

12.

Reeve

Deprescribing tools: a review of the types of tools available to aid deprescribing in clinical practice. J Pharm Pract Res 2020; 50: 98–107.